|
2017 Journal Article The decline of medical publishing: the rise of the pseudo-journalDelahunt, Brett, Samaratunga, Hemamali and Egevad, Lars (2017). The decline of medical publishing: the rise of the pseudo-journal. Pathology, 49 (7), 673-674. doi: 10.1016/j.pathol.2017.08.001 |
|
2017 Journal Article Pathology Imagebase-a reference image database for standardization of pathologyEgevad, Lars, Cheville, John, Evans, Andrew J., Hornblad, Jonas, Kench, James G., Kristiansen, Glen, Leite, Katia R. M., Magi-Galluzzi, Cristina, Pan, Chin-Chen, Samaratunga, Hemamali, Srigley, John R., True, Lawrence, Zhou, Ming, Clements, Mark and Delahunt, Brett (2017). Pathology Imagebase-a reference image database for standardization of pathology. Histopathology, 71 (5), 677-685. doi: 10.1111/his.13313 |
|
2017 Journal Article Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cellsKryza, Thomas, Silva, Lakmali M., Bock, Nathalie, Fuhrman-Luck, Ruth, Stephens, Carson, Gao, Jin, Samaratunga, Hema, Lawrence, Mitchell, Hooper, John D., Dong, Ying, Risbridger, Gail and Clements, Judith A. (2017). Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Molecular Oncology, 11 (10), 1307-1329. doi: 10.1002/1878-0261.12075 |
|
2017 Journal Article Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 casesSamaratunga, Hemamali, Delahunt, Brett, Srigley, John R., Yaxley, John, Johannsen, Shulammite, Coughlin, Geoffrey, Gianduzzo, Troy, Kua, Boon, Patterson, Imogen, Nacey, John N. and Egevad, Lars (2017). Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 71 (4), 641-647. doi: 10.1111/his.13278 |
|
2017 Journal Article Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology gradingDagher, Julien, Delahunt, Brett, Rioux-Leclercq, Nathalie, Egevad, Lars, Srigley, John R, Coughlin, Geoffrey, Dunglinson, Nigel, Gianduzzo, Troy, Kua, Boon, Malone, Greg, Martin, Ben, Preston, John, Pokorny, Morgan, Wood, Simon, Yaxley, John and Samaratunga, Hemamali (2017). Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading. Histopathology, 71 (6), 918-925. doi: 10.1111/his.13311 |
|
2017 Conference Publication PIRADS 3 lesions characterised by mp-MRI of the prostate correspond with an intermediate to high risk of clinically significant prostate cancer on whole specimen histopathology - a retrospective review of 42 casesScott, Susan E., Gianduzzo, Troy, Coughlin, Geoff, Kua, Boon, Parkinson, Rob, Samaratunga, Hemamali and Yaxley, John (2017). PIRADS 3 lesions characterised by mp-MRI of the prostate correspond with an intermediate to high risk of clinically significant prostate cancer on whole specimen histopathology - a retrospective review of 42 cases. ANZUP Annual Scientific Meeting - The Art & Science of Best Practice, Melbourne, VIC Australia, 16–18 July 2017. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2017 Journal Article UICC drops the ball in the 8th edition TNM staging of urological cancersDelahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Varma, Murali, Verrill, Clare, Cheville, John, Kristiansen, Glen, Corbishley, Catherine and Berney, Daniel M. (2017). UICC drops the ball in the 8th edition TNM staging of urological cancers. Histopathology, 71 (1), 5-11. doi: 10.1111/his.13200 |
|
2017 Journal Article Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 yearsYaxley, John W., Lah, Kevin, Yaxley, Julian P., Gardiner, Robert A., Samaratunga, Hema and MacKean, James (2017). Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU International, 120 (1), 56-60. doi: 10.1111/bju.13659 |
|
2017 Journal Article Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limitedSiriwardana, Amila, Thompson, James, van Leeuwen, Pim J., Doig, Shaela, Kalsbeek, Anton, Emmett, Louise, Delprado, Warick, Wong, David, Samaratunga, Hemamali, Haynes, Anne-Maree, Coughlin, Geoff and Stricker, Phillip (2017). Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU International, 120 (5), 673-681. doi: 10.1111/bju.13919 |
|
2017 Conference Publication Diagnostic potential of PSMA PET in advanced renal cell carcinomaNicholson, C., Joshi, A., Rhee, H., Tham, M., Thomas, P., Blazak, J., Samaratunga, H., Ng, K. L., Globe, G., Vela, I. and Wood, S. (2017). Diagnostic potential of PSMA PET in advanced renal cell carcinoma. 70th Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Canberra, ACT Australia, 24-27 February 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13750 |
|
2017 Journal Article Editorial comment to biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer RotterdamEgevad, Lars, Samaratunga, Hemamali and Delahunt, Brett (2017). Editorial comment to biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 24 (4), 286-287. doi: 10.1111/iju.13305 |
|
2017 Journal Article Prostate cancer grading: a decade after the 2005 modified Gleason grading systemDelahunt, Brett, Grignon, David J., Samaratunga, Hemamali, Srigley, John R., Leite, Katia R. M., Kristiansen, Glen, Evans, Andrew J., Kench, James G. and Egevad, Lars (2017). Prostate cancer grading: a decade after the 2005 modified Gleason grading system. Archives of Pathology and Laboratory Medicine, 141 (2), 182-183. doi: 10.5858/arpa.2016-0300-LE |
|
2017 Conference Publication Expression of prostate specific membrane antigen in clear cell renal cell carcinoma, neovasculature of tumour, and circulating tumour cellsNicholson, C., Rhee, H., Ng, K. L., Tse, B. W., Yeh, M-C, Russell, P., Nelson, C., Thomas, P., Samaratunga, H., Vela, I., Gobe, G. and Wood, S. (2017). Expression of prostate specific membrane antigen in clear cell renal cell carcinoma, neovasculature of tumour, and circulating tumour cells. 70th Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Canberra, ACT Australia, 24-27 February 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13750 |
|
2016 Journal Article Editorial statement on Gleason scoring for prostate cancer: in regard to Zietman et alEgevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). Editorial statement on Gleason scoring for prostate cancer: in regard to Zietman et al. International Journal of Radiation Oncology - Biology - Physics, 96 (5), 1126-1127. doi: 10.1016/j.ijrobp.2016.08.029 |
|
2016 Journal Article New Gleason grading system: statement from the editors of 6 journalsEgevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). New Gleason grading system: statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 34 (11), 479-480. doi: 10.1016/j.urolonc.2016.07.003 |
|
2016 Journal Article Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced diseaseRhee, Handoo, Ng, Keng Lim, Tse, Brian Wan-Chi, Yeh, Mei-Chun, Russell, Pamela J., Nelson, Colleen, Thomas, Paul, Samaratunga, Hemamali, Vela, Ian, Gobe, Glenda and Wood, Simon (2016). Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology, 48 (6), 613-616. doi: 10.1016/j.pathol.2016.05.011 |
|
2016 Journal Article One is the new six: the international society of urological pathology (ISUP) patient-focused approach to Gleason gradingSrigley, John R., Delahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Yaxley, John and Evans, Andrew J. (2016). One is the new six: the international society of urological pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 10 (9-10), 339-341. doi: 10.5489/cuaj.4146 |
|
2016 Journal Article Reply by the authorsEgevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). Reply by the authors. Urology, 96, 179-180. doi: 10.1016/j.urology.2016.07.006 |
|
2016 Journal Article Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 studyYaxley, John W., Coughlin, Geoffrey D., Chambers, Suzanne K., Occhipinti, Stefano, Samaratunga, Hema, Zajdlewicz, Leah, Dunglison, Nigel, Carter, Rob, Williams, Scott, Payton, Diane J., Perry-Keene, Joanna, Lavin, Martin F. and Gardiner, Robert A. (2016). Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. The Lancet, 388 (10049), 1057-1066. doi: 10.1016/S0140-6736(16)30592-X |
|
2016 Journal Article Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocolRoberts, Matthew J., Yaxley, John W., Coughlin, Geoffrey D., Gianduzzo, Troy R. J., Esler, Rachel C., Dunglison, Nigel T., Chambers, Suzanne K., Medcraft, Robyn J., Chow, Clement W. K., Schirra, Horst Joachim, Richards, Renee S., Kienzle, Nicholas, Lu, Macy, Brereton, Ian, Samaratunga, Hema, Perry-Keene, Joanna, Payton, Diane, Oyama, Chikara, Doi, Suhail A., Lavin, Martin F. and Gardiner, Robert A. (2016). Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol. Contemporary Clinical Trials, 50, 16-20. doi: 10.1016/j.cct.2016.06.014 |
